Eli Lilly to acquire Dice Therapeutics for $2.4B



Eli Lilly and Co. announced on Tuesday it has agreed to buy biopharma company DICE Therapeutics Inc. for around $2.4 billion or $48 per share in cash to boost its autoimmune drug portfolio.

“In …

About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento